Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

Locatelli, Franco; Zugmaier, Gerhard; Rizzari, Carmelo; Morris, Joan; Gruhn, Bernd; Klingebiel, Thomas; Parasole, Rosanna; Linderkamp, Christin; Flotho, Christian; Petit, Arnaud; Micalizzi, Concetta; Mergen, Noemi; Mohammad, Abeera; Kormany, William; Eckert, Cornelia; Möricke, Anja; Sartor, Mary; Hrušák, Ondřej; Peters, Christina; Saha, Vaskar; Vinti, Luciana; von Stackelberg, Arend

doi:10.1001/jama.2021.0987

Public

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

Published in JAMA • Mar 2, 2021

Authors:

Franco Locatelli

Gerhard Zugmaier

Carmelo Rizzari

Abstract

Importance: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Objective: To evaluate event-free survival in children with high-risk first-relapse B-ALL after a third consolidation ...

Subject

Medicine

Blinatumomab

Lymphoblastic Leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!